





SPACS 2016

Eastgate Biotech CORP
Rank 20 of 20

The relative strengths and weaknesses of Eastgate Biotech CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eastgate Biotech CORP compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 23% points. The greatest weakness of Eastgate Biotech CORP is the variable Assets, reducing the Economic Capital Ratio by 261% points.

The company's Economic Capital Ratio, given in the ranking table, is 87%, being 415% points below the market average of 502%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	114	Assets	298
Assets, Non-Current	0	Liabilities	2,779
General And Administrative Expense	2,542	Expenses	4,303
Liabilities, Current	2,729	Revenues	132
Liabilities, Non-Current	0	Stockholders Equity	-2,481
Other Assets	184	Net Income	-4,281
Other Compr. Net Income	17	Comprehensive Net Income	-4,265
Other Expenses	1,625	BaseVar	3,819
Other Liabilities	50	ECR before LimitedLiability	-1,084%
Other Net Income	-110	Economic Capital Ratio	87%
Other Revenues	132		
Professional Fees	137		